Current Appointments & Affiliations
Assistant Professor of Medicine
·
2021 - Present
Medicine, Pulmonary, Allergy, and Critical Care Medicine,
Medicine
Member in the Duke Clinical Research Institute
·
2021 - Present
Duke Clinical Research Institute,
Institutes and Centers
Recent Publications
Extent of lung fibrosis is of greater prognostic importance than HRCT pattern in patients with progressive pulmonary fibrosis: data from the ILD-PRO registry.
Journal Article Respir Res · February 28, 2025 BACKGROUND: The prognostic value of patterns and quantitative measures of lung fibrosis on high-resolution computed tomography (HRCT) in patients identified as having progressive pulmonary fibrosis (PPF) has not been established. We investigated whether HR ... Full text Link to item CiteDevelopment and evaluation of a questionnaire to capture environmental and occupational inhalational exposures in adults with fibrotic interstitial lung disease.
Journal Article Respir Res · October 15, 2024 BACKGROUND: Identification of exposures in patients with interstitial lung diseases (ILDs) is essential for diagnosis and management and can be facilitated through the use of exposure questionnaires. However, for most ILDs, a patient-focused questionnaire ... Full text Link to item CiteDesign and baseline characteristics of the ILD-PRO registry in patients with progressive pulmonary fibrosis.
Journal Article BMC Pulm Med · September 27, 2024 BACKGROUND: To assess the characteristics of patients enrolled in the ILD-PRO Registry. METHODS: The ILD-PRO Registry is a multicentre US registry of patients with progressive pulmonary fibrosis. This registry is enrolling patients with an interstitial lun ... Full text Link to item CiteRecent Grants
SEVERE COUGH A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary f
Clinical TrialPrincipal Investigator · Awarded by Boehringer Ingelheim Pharmaceuticals, Inc. · 2024 - 2029IM027-1015 BMS A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis
Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2023 - 2028BMS IM027-068 IPF A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis
Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2023 - 2028View All Grants
Education, Training & Certifications
Case Western Reserve University, School of Medicine ·
2012
M.D.